Clinical impact of clonal hematopoiesis in acute myeloid leukemia patients receiving allogeneic transplantation
Authors:
- 30 November 2018
- journal article
- research article
- Published by Springer Nature in Bone Marrow Transplantation
- Vol. 54 (8) , 1189-1197
Abstract
Age-related somatic mutations linked to clonal hematopoiesis have been found in apparently healthy individuals and increase the risk of developing hematologic malignancies. In acute myeloid leukemia (AML) the clinical relevance of clonal hematopoiesis remains controversial and data on patients with detectable clonal hematopoiesis, consolidated with hematopoietic stem cell transplantation are limited. We analyzed samples from 113 AML patients in complete remission prior to hematopoietic stem cell transplantation for the presence of clonal hematopoiesis-associated mutations. The results were correlated with clinical and biological data. In complete remission we found 75 mutations previously linked to clonal hematopoiesis in 47 patients (41.6%). Twenty patients had ≥2 mutations linked to clonal hematopoiesis. DNMT3A, TET2, and ASXL1 were most frequently mutated. When compared to pre-treatment samples we found variable patterns of mutation persistence depending on the gene mutated. In AML patients after allogeneic hematopoietic stem cell transplantation the presence of clonal hematopoiesis-associated mutations in complete remission did not associate with inferior clinical outcome. This study demonstrates that clonal hematopoiesis is a frequent phenomenon in AML patients. Presence of clonal hematopoiesis has no negative prognostic impact in the context of an allogeneic hematopoietic stem cell transplantation and might be beneficial if certain genes are affected.Keywords
This publication has 38 references indexed in Scilit:
- Systematic identification of personal tumor-specific neoantigens in chronic lymphocytic leukemiaBlood, 2014
- Identification of pre-leukaemic haematopoietic stem cells in acute leukaemiaNature, 2014
- Preleukemic mutations in human acute myeloid leukemia affect epigenetic regulators and persist in remissionProceedings of the National Academy of Sciences, 2014
- ASXL1 mutations identify a high-risk subgroup of older patients with primary cytogenetically normal AML within the ELN Favorable genetic categoryBlood, 2011
- Safety and Efficacy of TG101348, a Selective JAK2 Inhibitor, in MyelofibrosisJournal of Clinical Oncology, 2011
- Safety and Efficacy of INCB018424, a JAK1 and JAK2 Inhibitor, in MyelofibrosisNew England Journal of Medicine, 2010
- Nonmyeloablative Allogeneic Hematopoietic Cell Transplantation in Patients With Acute Myeloid LeukemiaJournal of Clinical Oncology, 2010
- IDH1 and IDH2 Gene Mutations Identify Novel Molecular Subsets Within De Novo Cytogenetically Normal Acute Myeloid Leukemia: A Cancer and Leukemia Group B StudyJournal of Clinical Oncology, 2010
- Rapid and sensitive screening for CEBPA mutations in acute myeloid leukaemiaBritish Journal of Haematology, 2008
- Treatment for Acute Myelogenous Leukemia by Low-Dose, Total-Body, Irradiation-Based Conditioning and Hematopoietic Cell Transplantation From Related and Unrelated DonorsJournal of Clinical Oncology, 2006